{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:53:55Z","timestamp":1791899635419,"version":"4.3.4"},"reference-count":131,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CIHR (Canadian Institutes of Health Research)","award":["154485"],"award-info":[{"award-number":["154485"]}]},{"name":"CIHR (Canadian Institutes of Health Research)","award":["22019"],"award-info":[{"award-number":["22019"]}]},{"name":"CIHR (Canadian Institutes of Health Research)","award":["RGPIN-2017-05752"],"award-info":[{"award-number":["RGPIN-2017-05752"]}]},{"name":"CRS (Cancer Research Society)","award":["154485"],"award-info":[{"award-number":["154485"]}]},{"name":"CRS (Cancer Research Society)","award":["22019"],"award-info":[{"award-number":["22019"]}]},{"name":"CRS (Cancer Research Society)","award":["RGPIN-2017-05752"],"award-info":[{"award-number":["RGPIN-2017-05752"]}]},{"DOI":"10.13039\/501100000038","name":"NSERC (Natural Sciences and Engineering Research Council of Canada)","doi-asserted-by":"publisher","award":["154485"],"award-info":[{"award-number":["154485"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC (Natural Sciences and Engineering Research Council of Canada)","doi-asserted-by":"publisher","award":["22019"],"award-info":[{"award-number":["22019"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC (Natural Sciences and Engineering Research Council of Canada)","doi-asserted-by":"publisher","award":["RGPIN-2017-05752"],"award-info":[{"award-number":["RGPIN-2017-05752"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple Myeloma (MM) is a B cell malignancy marked by genomic instability that arises both through pathogenesis and during disease progression. Despite recent advances in therapy, MM remains incurable. Recently, it has been reported that DNA repair can influence genomic changes and drug resistance in MM. The dysregulation of DNA repair function may provide an alternative explanation for genomic instability observed in MM cells and in cells derived from MM patients. This review provides an overview of DNA repair pathways with a special focus on their involvement in MM and discusses the role they play in MM progression and drug resistance. This review highlights how unrepaired DNA damage due to aberrant DNA repair response in MM exacerbates genomic instability and chromosomal abnormalities, enabling MM progression and drug resistance.<\/jats:p>","DOI":"10.3390\/ijms23105688","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T12:25:57Z","timestamp":1652963157000},"page":"5688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Role of DNA Repair in Genomic Instability of Multiple Myeloma"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-8472","authenticated-orcid":false,"given":"Jana Yasser Hafez","family":"Ali","sequence":"first","affiliation":[{"name":"Biophysics Department, Faculty of Science, Cairo University, Giza 12613, Egypt"},{"name":"Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-961X","authenticated-orcid":false,"given":"Amira Mohammed","family":"Fitieh","sequence":"additional","affiliation":[{"name":"Biophysics Department, Faculty of Science, Cairo University, Giza 12613, Egypt"},{"name":"Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-6063","authenticated-orcid":false,"given":"Ismail Hassan","family":"Ismail","sequence":"additional","affiliation":[{"name":"Biophysics Department, Faculty of Science, Cairo University, Giza 12613, Egypt"},{"name":"Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"ref_1","first-page":"1178224219868235","article-title":"Multiple myeloma: An overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: Pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"ref_4","unstructured":"Albagoush, S.A., and Azevedo, A.M. (2021). Multiple Myeloma, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clml.2020.01.017","article-title":"Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","volume":"20","author":"Bergstrom","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1515\/cclm-2015-0580","article-title":"Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fgene.2019.00424","article-title":"Germline Risk Contribution to Genomic Instability in Multiple Myeloma","volume":"10","author":"Janz","year":"2019","journal-title":"Front. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis","volume":"66","author":"Dewald","year":"1985","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1084\/jem.185.4.609","article-title":"Changes in locus-specific V(D)J recombinase activity induced by immunoglobulin gene products during B cell development","volume":"185","author":"Constantinescu","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1084\/jem.20091280","article-title":"Switch recombination and somatic hypermutation are controlled by the heavy chain 3\u2019 enhancer region","volume":"206","author":"Dunnick","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.trecan.2020.05.006","article-title":"Genomic Instability in Multiple Myeloma","volume":"6","author":"Alagpulinsa","year":"2020","journal-title":"Trends Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/cells10081961","article-title":"A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics","volume":"10","author":"Thapa","year":"2021","journal-title":"Cells"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.seminoncol.2013.07.010","article-title":"Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets","volume":"40","author":"Lawasut","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alhmoud, J.F., Woolley, J.F., Al Moustafa, A.-E., and Malki, M.I. (2020). DNA Damage\/Repair Management in Cancers. Cancers, 12.","DOI":"10.3390\/cancers12041050"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood.V120.21.3981.3981","article-title":"The Polymorphisms of Base Excision Repair Genes Influence the Prognosis of Multiple Myeloma","volume":"120","author":"Ushie","year":"2012","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/epi.1.3.2938","article-title":"DNA hypermethylation and partial gene silencing of human thymine\u2014DNA glycosylase in multiple myeloma cell lines","volume":"1","author":"Peng","year":"2006","journal-title":"Epigenetics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1074\/jbc.M412566200","article-title":"Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6\/1 cells","volume":"280","author":"Peng","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/leu.2017.182","article-title":"Nucleotide excision repair is a potential therapeutic target in multiple myeloma","volume":"32","author":"Szalat","year":"2018","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V120.21.2934.2934","article-title":"Impact of Single Nucleotide Polymorphisms in Genes Involved in DNA Repair and Drug Metabolism On Survival After Autologous Stem Cell Transplantation in Patients with Multiple Myeloma","volume":"120","author":"Navarro","year":"2012","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/1538-7445.AM2012-2634","article-title":"Abstract 2634: Polymorphisms in DNA repair genes and risk of multiple myeloma","volume":"72","author":"Rand","year":"2012","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.22411","article-title":"Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation","volume":"120","author":"Vangsted","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.yexmp.2008.02.003","article-title":"Aberrant gene promoter methylation in plasma cell dyscrasias","volume":"84","author":"Martin","year":"2008","journal-title":"Exp. Mol. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/modpathol.3800590","article-title":"hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies","volume":"19","author":"Martin","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/carcin\/bgh187","article-title":"DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma","volume":"25","author":"Velangi","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41375-018-0017-0","article-title":"Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: A role for PARP inhibition?","volume":"32","author":"Pawlyn","year":"2018","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fonc.2014.00289","article-title":"A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin","volume":"4","author":"Alagpulinsa","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.18632\/oncotarget.1740","article-title":"A DNA repair pathway score predicts survival in human multiple myeloma: The potential for therapeutic strategy","volume":"5","author":"Kassambara","year":"2014","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u2019\u2019 sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/jmg.39.12.900","article-title":"Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination","volume":"39","author":"Roddam","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1093\/hmg\/ddm273","article-title":"Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma","volume":"16","author":"Hayden","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","article-title":"The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1517\/14712598.2013.814637","article-title":"Genomic instability in multiple myeloma: Mechanisms and therapeutic implications","volume":"13","author":"Neri","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1158\/0008-5472.CAN-07-1015","article-title":"Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway Activation","volume":"67","author":"Jacquemont","year":"2007","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/blood-2018-99-119131","article-title":"Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance","volume":"132","author":"Bauer","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t (4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2020.01084","article-title":"Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences","volume":"11","author":"Stratigopoulou","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00412-011-0347-4","article-title":"DNA glycosylases: In DNA repair and beyond","volume":"121","author":"Jacobs","year":"2012","journal-title":"Chromosoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2741\/4555","article-title":"Base excision repair of oxidative DNA damage: From mechanism to disease","volume":"22","author":"Whitaker","year":"2017","journal-title":"Front. Biosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1093\/nar\/gkm605","article-title":"Defective DNA base excision repair in brain from individuals with Alzheimer\u2019s disease and amnestic mild cognitive impairment","volume":"35","author":"Weissman","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/genes4030375","article-title":"Abnormal base excision repair at trinucleotide repeats associated with diseases: A tissue-selective mechanism","volume":"4","author":"Goula","year":"2013","journal-title":"Genes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/ACI.0000000000000135","article-title":"8-Oxoguanine DNA glycosylase-1-driven DNA base excision repair: Role in asthma pathogenesis","volume":"15","author":"Ba","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12975-018-0680-5","article-title":"Enhancing Base Excision Repair of Mitochondrial DNA to Reduce Ischemic Injury Following Reperfusion","volume":"10","author":"Simon","year":"2019","journal-title":"Transl. Stroke Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41021-019-0119-6","article-title":"Mechanism and regulation of DNA damage recognition in nucleotide excision repair","volume":"41","author":"Kusakabe","year":"2019","journal-title":"Genes Environ."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrm3822","article-title":"Understanding nucleotide excision repair and its roles in cancer and ageing","volume":"15","author":"Marteijn","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.mad.2008.02.012","article-title":"DNA mismatch repair: Molecular mechanism, cancer, and ageing","volume":"129","author":"Hsieh","year":"2008","journal-title":"Mech. Ageing Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.dnarep.2018.08.010","article-title":"DNA mismatch repair preferentially safeguards actively transcribed genes","volume":"71","author":"Huang","year":"2018","journal-title":"DNA Repair"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.mrrev.2017.07.001","article-title":"DNA mismatch repair and its many roles in eukaryotic cells","volume":"773","author":"Liu","year":"2017","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer-the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0921-8777(00)00030-6","article-title":"Structure and function of mismatch repair proteins","volume":"460","author":"Yang","year":"2000","journal-title":"Mutat. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.74.082803.133243","article-title":"DNA mismatch repair","volume":"74","author":"Kunkel","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cell.2006.05.039","article-title":"Endonucleolytic function of MutLalpha in human mismatch repair","volume":"126","author":"Kadyrov","year":"2006","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1073\/pnas.1914718117","article-title":"Human MutL\u03b3, the MLH1-MLH3 heterodimer, is an endonuclease that promotes DNA expansion","volume":"117","author":"Kadyrova","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Miller, C.J., Kim, G.-Y., Zhao, X., and Usdin, K. (2020). All three mammalian MutL complexes are required for repeat expansion in a mouse cell model of the Fragile X-related disorders. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1008902"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3816\/CLM.2009.n.072","article-title":"Microsatellite instability is a common finding in multiple myeloma","volume":"9","author":"Demircin","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MOH.0b013e328353da3a","article-title":"The role of activation-induced cytidine deaminase in lymphomagenesis","volume":"19","author":"Gu","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood-2004-04-1558","article-title":"Expression of the AID protein in normal and neoplastic B cells","volume":"104","author":"Pasqualucci","year":"2004","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrm.2016.48","article-title":"The Fanconi anaemia pathway: New players and new functions","volume":"17","author":"Ceccaldi","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13578-020-00401-7","article-title":"Fanconi anemia pathway as a prospective target for cancer intervention","volume":"10","author":"Liu","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R986","DOI":"10.1016\/j.cub.2017.07.043","article-title":"Fanconi anemia pathway","volume":"27","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood-2002-07-2170","article-title":"A 20-year perspective on the International Fanconi Anemia Registry (IFAR)","volume":"101","author":"Kutler","year":"2003","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.febslet.2011.04.078","article-title":"Ubiquitylation and the Fanconi anemia pathway","volume":"585","author":"Garner","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lonial, S. (2008). Proteasome Inhibitors as Therapy in Multiple Myeloma. Myeloma Therapy: Pursuing the Plasma Cell, Humana Press.","DOI":"10.1007\/978-1-59745-564-0"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-09-2616","article-title":"Targeting the Fanconi anemia\/BRCA pathway circumvents drug resistance in multiple myeloma","volume":"69","author":"Yarde","year":"2009","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2041-9414-3-9","article-title":"Pathway choice in DNA double strand break repair: Observations of a balancing act","volume":"3","author":"Brandsma","year":"2012","journal-title":"Genome Integr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mrfmmm.2008.10.019","article-title":"Impaired NHEJ function in multiple myeloma","volume":"660","author":"Yang","year":"2009","journal-title":"Mutat. Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Setton, J., Bindra, R.S., and Powell, S.N. (2016). DNA double-strand repair by nonhomologous end joining and its clinical relevance. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications, Academic Press. [2nd ed.].","DOI":"10.1016\/B978-0-12-803582-5.00009-7"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/microbiolspec.MDNA3-0041-2014","article-title":"V(D)J Recombination: Mechanism, Errors, and Fidelity","volume":"2","author":"Roth","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1128\/MCB.01639-13","article-title":"53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks","volume":"34","author":"Daley","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.dnarep.2014.02.006","article-title":"Non-homologous end joining often uses microhomology: Implications for alternative end joining","volume":"17","author":"Pannunzio","year":"2014","journal-title":"DNA Repair"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.dnarep.2018.06.001","article-title":"Regulation of DNA repair in the absence of classical non-homologous end joining","volume":"68","author":"Kang","year":"2018","journal-title":"DNA Repair"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"a012757","DOI":"10.1101\/cshperspect.a012757","article-title":"Repair of double-strand breaks by end joining","volume":"5","author":"Chiruvella","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1541-7786.MCR-17-0373","article-title":"Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia","volume":"16","author":"Gassner","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1074\/jbc.TM117.000375","article-title":"Repair of DNA double-strand breaks by mammalian alternative end-joining pathways","volume":"293","author":"Sallmyr","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mrfmmm.2017.07.002","article-title":"Microhomology-mediated end joining: Good, bad and ugly","volume":"809","author":"Seol","year":"2018","journal-title":"Mutat. Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Herrero, A.B., San Miguel, J., and Gutierrez, N.C. (2015). Deregulation of DNA double-strand break repair in multiple myeloma: Implications for genome stability. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121581"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/10428194.2018.1551536","article-title":"Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: An IMMEnSE study","volume":"60","author":"Campa","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12026-012-8329-z","article-title":"Role of non-homologous end joining in V(D)J recombination","volume":"54","author":"Malu","year":"2012","journal-title":"Immunol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1073\/pnas.0409857102","article-title":"Artemis-independent functions of DNA-dependent protein kinase in Ig heavy chain class switch recombination and development","volume":"102","author":"Rooney","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"22953","DOI":"10.1073\/pnas.2007455117","article-title":"DNA-PKcs phosphorylation at the T2609 cluster alters the repair pathway choice during immunoglobulin class switch recombination","volume":"117","author":"Crowe","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1097-2765(01)00424-5","article-title":"NHEJ deficiency and disease","volume":"8","author":"Pierce","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/35006670","article-title":"DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation","volume":"404","author":"Difilippantonio","year":"2000","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1073\/pnas.94.15.8076","article-title":"Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination","volume":"94","author":"Gu","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V104.11.1414.1414","article-title":"VDJ-Switch Region Analysis in Multiple Myeloma Patients Reveals Homogeneity and Long-Term Stability of Switch Junctions, and Ongoing Mutation Upstream of Switch Mu","volume":"104","author":"Taylor","year":"2004","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Rowley, J.D., le Beau, M.M., and Rabbitts, T.H. (2015). Immunoglobulin and MYC Rearrangements in Multiple Myeloma Pathogenesis. Chromosomal Translocations and Genome Rearrangements in Cancer, Springer.","DOI":"10.1007\/978-3-319-19983-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"Chapman","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0022-2836(92)90681-9","article-title":"Characterization of DNA-binding and strand-exchange stimulation properties of y-RPA, a yeast single-strand-DNA-binding protein","volume":"227","author":"Alani","year":"1992","journal-title":"J. Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2005.12.041","article-title":"TopBP1 activates the ATR-ATRIP complex","volume":"124","author":"Kumagai","year":"2006","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.dnarep.2013.04.004","article-title":"PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks","volume":"12","author":"Metzger","year":"2013","journal-title":"DNA Repair"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1535-7163.MCT-15-0660","article-title":"A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition","volume":"15","author":"Alagpulinsa","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","article-title":"Dysfunctional homologous recombination mediates genomic instability and progression in myeloma","volume":"113","author":"Shammas","year":"2009","journal-title":"Blood"},{"key":"ref_105","unstructured":"Case Medical Research (2019). A phase 1\/2 study of CYT-0851, an oral RAD51 inhibitor. B-Cell Malignancies and Advanced Solid Tumors, Cyteir Therapeutics."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"HemaSphere"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","article-title":"DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells","volume":"52","author":"Zhao","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13578-020-00412-4","article-title":"BRCA1 and homologous recombination: Implications from mouse embryonic development","volume":"10","author":"Liu","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.dnarep.2018.11.008","article-title":"53BP1: A key player of DNA damage response with critical functions in cancer","volume":"73","author":"Mohammadzadeh","year":"2019","journal-title":"DNA Repair"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jnci\/94.6.461","article-title":"Re: Familial Multiple Myeloma: A Family Study and Review of the Literature","volume":"94","author":"Sobol","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.cell.2006.10.043","article-title":"Structural Basis for the Methylation State-Specific Recognition of Histone H4-K20 by 53BP1 and Crb2 in DNA Repair","volume":"127","author":"Botuyan","year":"2006","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1038\/onc.2016.116","article-title":"MMSET\/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents","volume":"35","author":"Shah","year":"2016","journal-title":"Oncogene"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-10-1302","article-title":"The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors","volume":"17","author":"Hudlebusch","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature09658","article-title":"MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites","volume":"470","author":"Pei","year":"2011","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4;14) multiple myeloma cells","volume":"117","author":"Popovic","year":"2011","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Poczta, A., Rogalska, A., and Marczak, A. (2021). Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches. J. Clin. Med. Res., 10.","DOI":"10.3390\/jcm10091841"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet-Loiseau, H., Corre, J., and Perrot, A. (2020). Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12123497"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2015.209","article-title":"Defining and treating high-risk multiple myeloma","volume":"29","author":"Usmani","year":"2015","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10409230903501819","article-title":"DNA interstrand crosslink repair in mammalian cells: Step by step","volume":"45","author":"Muniandy","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/tx00044a018","article-title":"Alkylation of DNA by the Nitrogen Mustard Bis-(2-chloroethyl) methylamine","volume":"8","author":"Osborne","year":"1995","journal-title":"Chem. Res. Toxicol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Sousa, M.M.L., Zub, K.A., Aas, P.A., Hanssen-Bauer, A., and Demirovic, A. (2013). An Inverse Switch in DNA Base Excision and Strand Break Repair Contributes to Melphalan Resistance in Multiple Myeloma Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055493"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: Mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcade) in the Treatment of Multiple Myeloma","volume":"2","author":"Morgan","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-\u03baB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a Primary Target of Thalidomide Teratogenicity","volume":"327","author":"Takumi","year":"2010","journal-title":"Science"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.leukres.2011.02.009","article-title":"Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide","volume":"35","author":"Cibeira","year":"2011","journal-title":"Leukemia Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:14:51Z","timestamp":1760138091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":131,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105688"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105688","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}